(Q37980546)

26 August 2017

title

An expert opinion on the current treatment of anemia in patients with kidney disease (English)

1 reference

26 August 2017

1

Francesco Locatelli

1 reference

26 August 2017

Lucia Del Vecchio

2

1 reference

26 August 2017

language of work or name

English

0 references

publication date

2 February 2012

1 reference

Expert Opinion on Pharmacotherapy

26 August 2017

published in

1 reference

26 August 2017

volume

13

1 reference

26 August 2017

issue

4

1 reference

26 August 2017

page(s)

495-503

1 reference

Pathogenesis of oedema in chronic severe anaemia: studies of body water and sodium, renal function, haemodynamic variables, and plasma hormones

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658369

Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658369

Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658369

Evidence-based systematic literature review of hemoglobin/hematocrit and all-cause mortality in dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658369

Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658369

Human erythropoietin gene: high level expression in stably transfected mammalian cells and chromosome localization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658369

The regulatory framework of biosimilars in the European Union.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658369

Assessing the bioequivalence of biosimilars The Retacrit case

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658369

Quality of original and biosimilar epoetin products

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658369

Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658369

Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658369

Clinical implications of converting stable haemodialysis patients from subcutaneous to intravenous administration of darbepoetin alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658369

Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658369

Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658369

C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658369

C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658369

Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658369

Inflammation and resistance to treatment with recombinant human erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658369

Erythropoietin, iron depletion, and relative thrombocytosis: a possible explanation for hemoglobin-survival paradox in hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658369

Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658369

Normalization of hemoglobin level in patients with chronic kidney disease and anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658369

Transfusion burden among patients with chronic kidney disease and anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658369

Association of quarterly average achieved hematocrit with mortality in dialysis patients: a time-dependent comorbidity-adjusted model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658369

A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658369

Against TREATing all patients alike: lessons from an FDA Advisory Committee Meeting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658369

Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to reduce cardiovascular events with Aranesp therapy (TREAT) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658369

Erythropoietic Response and Outcomes in Kidney Disease and Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658369

Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658369

Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658369

10.1517/14656566.2012.658369

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference